Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction
- 958 Downloads
KeywordsEnteric Nervous System Myenteric Plexus Enteric Neuron Myenteric Ganglion Distended Abdomen
Anti-smooth muscle actin
Chronic intestinal pseudo-obstruction
Enteric nervous system
Gastrointestinal neuromuscular disorders
High power field
Interstitial cells of Cajal
Chronic intestinal pseudo-obstruction (CIPO) represents a rare and severe condition characterized by failure of the intestinal tract to propel its contents normally [1, 2]. The condition presents with clinical features such as abdominal pain, vomiting, distended abdomen, constipation, and diarrhea [1, 2]. These symptoms resemble an intestinal mechanical obstruction in the absence of a demonstrable lesion occluding the gut. It is thought that this can result from disturbance of the intestinal motor function, supplied by the enteric nervous system (ENS). The neurons of the ENS are contained in two groups of ganglia: the myenteric (Auerbach's) and the submucosal (Meissner's) plexuses.
The ENS has the unique ability to control most gut functions, such as regulating vascular tone, secretion/absorption, and gut motility [3, 4]. Given these important functions of the ENS, it is not surprising that damage to the ENS results in digestive disorders and reduced quality of life. Human and experimental evidence indicates that inflammation can occur in the ENS, resulting in severe intestinal motor impairment. Inflammation of the ENS has indeed been observed in some cases of CIPO [3, 5, 6].
Many efforts have been made to classify CIPO. Based on histological examination, CIPO may be categorized as primary, secondary, or idiopathic in nature . Primary CIPO can be classified into three major categories of gastrointestinal neuromuscular disorders (GINMD): mesenchymopathies, myopathies, and neuropathies, depending on the predominant involvement of interstitial cells, smooth muscle cells, or enteric neurons, respectively [1, 7]. The enteric neuropathies underlying CIPO can be subdivided into two major entities: (a) degenerative neuropathies, without any evident inflammatory response and (b) inflammatory neuropathies, referred to as myenteric ganglionitis [3, 8]. Inflammation within the myenteric ganglia is a recognized primary cause of CIPO, but the mechanisms through which the dysfunction occurs and the mechanisms leading to enteric neuropathies remain poorly understood [3, 4]. In this case report, we present the first male neonate with eosinophilic myenteric ganglionitis underlying CIPO and report his successful recovery following steroid treatment.
A boy was born prematurely at 25 weeks through a primary Caesarean section, weighing 940 grams (> − 2.5 SD). Two weeks later he suffered from necrotizing enterocolitis for which he underwent a right hemicolectomy as well as resection of 10 cm of jejunum. However, in the months following surgery, the infant continued to have poor feeding tolerance with a distended abdomen and severe constipation. At 6 months of age, the boy weighed 4.1 kg (−2.5 SD), despite total parental feeding. At 4 months of age, he developed signs of obstruction (distended abdomen, vomiting, and gastric retentions) and a laparotomy was performed. During surgery, there was no stricture at the ileocolonic anastomosis. Although there was no stricture, a milk curd was found proximal to the anastomosis and the anastomosis was resected. Rectal full thickness biopsies were taken to rule out Hirschsprung's disease. The laboratory results showed a variable number of eosinophils (0.1 × 109/l to 1.0 × 109/l) and during a short period of time peripheral eosinophilia was present until treatment started. Laboratory results further showed a normal amount of serum IgE and tests for antinuclear and smooth muscle autoantibodies were negative. Because of the feeding difficulties, the patient was treated with an amino acid-based infant formula for 4 months. Major improvement of the infant's condition only occurred after starting anti-inflammatory treatment, using intravenous prednisone and subsequently oral beclomethasone 200 mg three times daily. Within 1–2 weeks after starting the beclomethasone, enteral nutrition could be increased to complete enteral feeding. After 6 months of hospitalization, the patient was discharged in good condition. Follow-up for 7 months after discharge showed that the patient still needs corticosteroids and steroid-containing enemas have been added to the therapy during flares of the gastrointestinal problems, which has a positive effect on his feeding tolerance. After 18 months of follow-up after hospitalization, the child eats normally and does not need any medication.
Materials and methods
Informed consent for publication was obtained from the parents.
A hemicolectomy specimen as well as 10 cm of jejunum was received. Later, full thickness rectal biopsies were taken during surgery for a pseudo-obstruction as well as the anastomosis created during the previous surgery. Histological sections were prepared and examined by routine methods. Enzyme histochemistry with acetylcholinesterase was performed on frozen sections of the biopsies to exclude Hirschsprung's disease. Immunohistochemistry using CD117 was applied on formalin-fixed paraffin-embedded sections form the resection specimen to demonstrate the presence of interstitial cells of Cajal (ICCs). The number of eosinophils per high power field (HPF, i.e., 400×) was counted in the resection specimens.
On the same slides, we performed immunohistochemical analysis with PGP9.5 to demonstrate the presence of enteric neurons. In addition, we applied anti-smooth muscle actin (anti-SMA) to demonstrate the presence of a normal layer of smooth muscle.
Immunohistochemical analysis with PGP9.5 showed the presence of an apparently normal number of enteric neurons, even with the presence of eosinophils in the immediate vicinity (Fig. 2c). This indicates that the eosinophilic infiltrate did not lead to degeneration of the neurons. In addition we used immunohistochemical analysis with antibodies against smooth muscle actin (anti-SMA) to show there was a normal amount of smooth muscle cells (Fig. 2d).
We describe the second neonatal case of eosinophilic myenteric ganglionitis, causing a rare and highly morbid functional intestinal obstruction syndrome, referred to as CIPO . This represents a rare syndrome characterized by impaired gastrointestinal propulsion, which causes symptoms of gastrointestinal obstruction, in the absence of any lesion occluding the intestinal lumen . The intestine depends on the ENS for its functionally important patterns of movement . Current evidence indicates that alterations in the ENS, including functional impairment of neurons, are associated with uncoordinated motor activities, resulting in altered transit of intestinal contents potentially leading to CIPO .
Schappi et al.  described three cases, all female in contrast to our patient. The three cases described were aged 1 month, 11 and 15 years. The clinical presentation of the first two patients is similar to our case: vomiting, constipation, and marked abdominal distension for several days. The third case had a more acute event. The neonate also experienced a peripheral blood eosinophilia (1.15 × 109/l) as did our case before he was treated. However, in our case there was no elevation in serum IgE, as was described in the first two cases. Smooth muscle and antinuclear autoantibodies were weakly positive in the neonatal case, not described in the second, and negative in the third case as in our patient. In our patient no anorectal inflammatory manometry was performed.
In our patient the clinical picture was obscured at first by necrotizing enterocolitis in this premature infant. However, after surgery the patient continued to have feeding difficulties. The patient developed signs of a gastrointestinal obstruction, but during surgery this turned out to be a pseudo-obstruction. When examining the bowel specimen, it was noticed that there was an eosinophilic myenteric ganglionitis. The eosinophils were specifically located around the ganglion cells, with some scattered eosinophils in the submucosa and tunica muscularis. In the second and third cases described by Schappi et al. there seems to be a more extensive involvement of all layers of the bowel, but with a larger collection of eosinophils around the myenteric plexus. Unfortunately, they do not provide a count of the eosinophils. IL-5, a potent eosinophil chemoattractant, has been suggested as a humoral factor playing a role in gut dysmotility. IL-5 expression by the myenteric ganglions was demonstrated by Schappi et al. in his patients with eosinophilic myenteric ganglionitis. Unfortunately we did not have the means to demonstrate IL-5 expression in our patient.
In the neonatal case and the second case of Schappi et al. Hirschsprung's disease was considered, as was done in our case. Full thickness rectal biopsies in those children and in our case also showed the presence of normal ganglia and neurons within the submucosal and myenteric plexus, as well as a normal acetylcholinesterase staining pattern. In all cases described as well as in our case, there was no significant lymphocytic infiltrate.
We applied immunohistochemistry with CD117 antibodies to analyze the number of interstitial cells of Cajal, which are thought to be required for normal gut motility and are also implicated in some forms of GINMD. ICCs are found widespread throughout the gastrointestinal tract, distributed along a variety of locations. In the colon, distinct networks can be found in the myenteric plexus and more loosely in the submucosa. In the small bowel, the same networks can be found in the myenteric plexus and in addition more loosely in the deep muscular plexus. Single ICCs can also be found interspersed between muscle cells in the muscle layer [10, 11]. CD117 also stains mast cells, which were excluded by comparing with the H&E and by looking at the contour of the cell, since mast cells do not have processes whereas ICCs do [10, 11]. Until now, there are no normal reference values for the range of ICC numbers when applying immunohistochemistry. Most reports use immunofluorescence on frozen tissue samples instead of immunohistochemistry on paraffin-embedded material [10, 11]. It is believed that immunohistochemistry does not detect all ICCs . Therefore, we examined our slides for the presence of the ICCs in the previously named locations, especially in those with the presence of eosinophils. In addition we used PGP-9.5 and anti-SMA to demonstrate the presence of a normal amount of enteric neurons and smooth muscle cells, respectively. These immunohistochemical stainings also showed a normal amount of neurons and smooth muscle cells.
By excluding the above-mentioned cells as a cause of the pseudo-obstruction, it appears more likely that there is a functional rather than anatomically detectable cause for the pseudo-obstruction in this patient. However, we cannot entirely exclude this, as we have not performed quantitative analysis of the enteric neurons. Similar to the patients demonstrated by Schappi et al. there was no clinical improvement in the gastrointestinal dysmotility syndrome with an amino acid-based formula as the sole source of nutrition for at least 3 months in our patient as compared to 2 months in the neonatal case described by Schappi et al. However, all patients, including our patient, did respond rapidly to steroids . We used the same steroid (beclomethason) in the same dosage as in the previously published neonatal case. The other cases were treated with (methyl)prednisolone and azathioprine. Our patient could tolerate complete enteral feeding within 1–2 weeks. In contrast to the previously published patients, our patient is completely without medication after 18 months of follow-up, not requiring a maintenance dose of steroids.
In conclusion, this case illustrates that a GINMD, such as myenteric ganglionitis, should be considered in patients with CIPO, since it may be treated with an elemental diet and steroids.
Conflict of interest statement
We declare that we have no conflict of interest.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- 5.De Giorgio R, Barbara G, Stanghellini V, De Ponti F, Salvioli B, Tonini M, Velio P, Bassotti G, Corinaldesi R (2002) Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol 97(9):2454–2459. doi: 10.1111/j.1572-0241.2002.06002.x PubMedCrossRefGoogle Scholar
- 7.Knowles CH, De Giorgio R, Kapur RP, Bruder E, Farrugia G, Geboes K, Lindberg G, Martin JE, Meier-Ruge WA, Milla PJ, Smith VV, Vandervinden JM, Veress B, Wedel T (2010) The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut 59(7):882–887PubMedCrossRefGoogle Scholar
- 8.Di Nardo G, Blandizzi C, Volta U, Colucci R, Stanghellini V, Barbara G, Del Tacca M, Tonini M, Corinaldesi R, De Giorgio R (2008) Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 28(1):25–42. doi: 10.1111/j.1365-2036.2008.03707.x PubMedCrossRefGoogle Scholar
- 11.Gomez-Pinilla PJ, Gibbons SJ, Sarr MG, Kendrick ML, Shen KR, Cima RR, Dozois EJ, Larson DW, Ordog T, Pozo MJ, Farrugia G (2011) Changes in interstitial cells of cajal with age in the human stomach and colon. Neurogastroenterol Motil 23(1):36–44. doi: 10.1111/j.1365-2982.2010.01590.x, Epub 02010 Aug 01519PubMedCrossRefGoogle Scholar